Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine.

Kassam K, Davidson R, Tadrous PJ, Kumar M.

Case Rep Med. 2013;2013:975131. doi: 10.1155/2013/975131. Epub 2013 Sep 30.

2.

In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.

Coelho AC, Trinconi CT, Costa CH, Uliana SR.

PLoS Negl Trop Dis. 2014 Jul 17;8(7):e2999. doi: 10.1371/journal.pntd.0002999. eCollection 2014 Jul.

3.

Two cases of cutaneous leishmaniasis in Dutch military personnel treated with oral miltefosine.

van der Snoek EM, Couwenberg SM, Stijnis C, Kortbeek LM, Schadd EM.

J R Army Med Corps. 2017 Feb;163(1):68-70. doi: 10.1136/jramc-2015-000530. Epub 2015 Dec 9.

PMID:
26661280
4.

Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.

Reimão JQ, Oliveira JC, Trinconi CT, Cotrim PC, Coelho AC, Uliana SR.

PLoS Negl Trop Dis. 2015 Feb 13;9(2):e0003556. doi: 10.1371/journal.pntd.0003556. eCollection 2015 Feb.

5.

Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.

Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y.

Am J Trop Med Hyg. 2006 Dec;75(6):1074-7.

PMID:
17172368
6.
7.

[Eco-epidemiology of visceral and cutaneous leishmaniasis in the Yemen Arab Republic. I. Presence, in sympatric condition, of Leishmania infantum and Leishmania donovani complexes].

Rioux JA, Dereure J, Daoud W, el Kubati Y, Rageh HA, Moreno G, Pratlong F.

Bull Soc Pathol Exot Filiales. 1989;82(5):658-64. French.

PMID:
2633874
8.

Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes.

Carnielli JB, de Andrade HM, Pires SF, Chapeaurouge AD, Perales J, Monti-Rocha R, Carvalho SF, Ribeiro LP, Dietze R, Figueiredo SG, Lemos EM.

J Proteomics. 2014 Aug 28;108:198-208. doi: 10.1016/j.jprot.2014.05.010. Epub 2014 May 27.

PMID:
24874972
9.
10.

Cutaneous leishmaniasis after travel to Cyprus and successful treatment with miltefosine.

Poeppl W, Walochnik J, Pustelnik T, Auer H, Mooseder G.

Am J Trop Med Hyg. 2011 Apr;84(4):562-5. doi: 10.4269/ajtmh.2011.10-0645.

11.

Resolution of tongue lesions caused by Leishmania infantum in a dog treated with the association miltefosine-allopurinol.

Foglia Manzillo V, Paparcone R, Cappiello S, De Santo R, Bianciardi P, Oliva G.

Parasit Vectors. 2009 Mar 26;2 Suppl 1:S6. doi: 10.1186/1756-3305-2-S1-S6.

12.

Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.

Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, Ostyn B, Dujardin JC, Rijal S, Vanaerschot M.

MBio. 2013 Oct 8;4(5):e00611-13. doi: 10.1128/mBio.00611-13.

13.

Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.

Am J Trop Med Hyg. 2009 Mar;80(3):336-8.

PMID:
19270277
14.

Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.

Stoeckle M, Holbro A, Arnold A, Neumayr A, Weisser M, Blum J.

Acta Trop. 2013 Oct;128(1):168-70. doi: 10.1016/j.actatropica.2013.07.002. Epub 2013 Jul 18.

PMID:
23871798
15.

A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.

Vacchina P, Norris-Mullins B, Carlson ES, Morales MA.

Parasit Vectors. 2016 Dec 1;9(1):621.

16.

Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.

Obonaga R, Fernández OL, Valderrama L, Rubiano LC, Castro Mdel M, Barrera MC, Gomez MA, Gore Saravia N.

Antimicrob Agents Chemother. 2014;58(1):144-52. doi: 10.1128/AAC.01023-13. Epub 2013 Oct 21.

17.

Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species.

Das M, Saudagar P, Sundar S, Dubey VK.

FEBS J. 2013 Oct;280(19):4807-15. doi: 10.1111/febs.12449. Epub 2013 Aug 23.

18.

FIRST REPORT OF CUTANEOUS LEISHMANIASIS CAUSED BY Leishmania (Leishmania) infantum chagasi IN AN URBAN AREA OF RIO DE JANEIRO, BRAZIL.

Lyra MR, Pimentel MI, Madeira Mde F, Antonio Lde F, Lyra JP, Fagundes A, Schubach Ade O.

Rev Inst Med Trop Sao Paulo. 2015 Sep-Oct;57(5):451-4. doi: 10.1590/S0036-46652015000500016.

19.

Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.

Godinho JL, Simas-Rodrigues C, Silva R, Ürmenyi TP, de Souza W, Rodrigues JC.

Int J Antimicrob Agents. 2012 Apr;39(4):326-31. doi: 10.1016/j.ijantimicag.2011.11.008. Epub 2012 Jan 9.

20.

Rapid identification of causative species in patients with Old World leishmaniasis.

Minodier P, Piarroux R, Gambarelli F, Joblet C, Dumon H.

J Clin Microbiol. 1997 Oct;35(10):2551-5.

Supplemental Content

Support Center